Evidence map›Paper›PMID 38886994›Full record

ArticleThe American journal of case reports2024

Extended Left Hemihapatectomy with Right Hepatic Artery Reconstruction for Primary Hepatic Neuroendocrine Neoplasm: A Brief Report.

Yin Jiang, Joseph Mugaanyi, Shi Wei Zhang, Gao Qing Wang, Yong Fei Hua, Ye-Ming Zhou, Caide Lu

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Primary Hepatic Neuroendocrine Neoplasms: Systematic Review and Expert Pathologist Reappraisal Using the WHO 6th Edition Framework.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  2. [Primary hepatic neuroendocrine neoplasms: a case series analysis of 10 patients and literature review].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yin JiangDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0009-0005-2444-046X
Joseph MugaanyiDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0000-0003-1688-5475
Shi Wei ZhangHealth Science Center, Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0009-0000-0462-8266
Gao Qing WangDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0000-0002-6277-8702
Yong Fei HuaDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0000-0001-5095-5639
Ye-Ming ZhouDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0000-0003-2560-8138
Caide LuDepartment of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China (mainland).ORCID 0000-0001-9588-2218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND rimary hepatic neuroendocrine neoplasms (PHNEN) are exceedingly rare tumors with atypical clinical manifestations, accounting for less than 0.5% of all neuroendocrine tumors. Currently, there is a lack of consensus on their management, and guidelines do not recommend postoperative chemotherapy for patients with stage G1/G2 disease after curative resection. We present a case report of PHNEN, outlining its diagnostic challenges, treatment strategy, and clinical outcomes. CASE REPORT A 31-year-old man presented with jaundice and was initially diagnosed with suspected IgG4-related disease, which initially appeared to respond to steroid therapy, but manifested worsening jaundice 4 months after initial treatment. Subsequent evaluation revealed a PHNEN NET G2 with lymph node metastasis and invasion of the right hepatic artery; and involvement of the hepatic duct at the hepatic hilum, primarily the left hepatic duct. The patient underwent extended left hemi-hepatectomy with caudate lobe resection, bile duct resection, and lymphadenectomy, followed by reconstruction of the right hepatic artery. Postoperatively, the patient received adjuvant chemotherapy consisting of capecitabine (1000 mg bid D1-14) and temozolomide (200 mg qn D10-14) for 6 cycles. Currently, the patient remains disease free 43 months after treatment. CONCLUSIONS PHNEN presents diagnostic challenges due to its rarity and lack of specific markers. Surgical resection remains the cornerstone of treatment, with chemotherapy being considered in select cases with high-risk features. Further research is needed to refine treatment approaches and improve outcomes for patients with PHNEN.

Indexed as

HepatectomyHepatic ArteryLiver NeoplasmsNeuroendocrine TumorsAdultHumansMale

Identifiers

PMID38886994
PMCPMC11660953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.